Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Santiago Bonanad Boix

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Medicina Clinica|February 18, 2004
[Cloning and stem cells]Ximo Soriano Felipe, Antonio Guerrero Espejo, Santiago Bonanad Boix
Clinical Case Reports|January 14, 2022
Cerebral calcium embolismPedro Asensi Cantó, Jürgen Solís Ruíz, Pilar Lloret Madrid, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|April 5, 2022
Monitoring coagulation factors during surgery. A systematic reviewJuan Eduardo Megías-Vericat, Santiago Bonanad-Boix, María Remedios Marqués-Miñana, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|September 1, 2022
Emicizumab-induced photosensitivityPedro Asensi Cantó, Mercedes Rodríguez Serna, Pilar Lloret Madrid, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|November 6, 2024
Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in the therapy of hemophilia A in clinical practiceMaria Choví-Trull, Juan Eduardo Megías-Vericat, Santiago Bonanad Boix, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|February 14, 2025
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practiceMaria Choví-Trull, Juan Eduardo Megías-Vericat, Santiago Bonanad Boix, et al.
Hematology Reports|October 28, 2025
Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A PatientsMaria Choví-Trull, Juan Eduardo Megías-Vericat, Santiago Bonanad-Boix, et al.
Thrombosis Research|January 13, 2026
Improvements in pharmacokinetics, bleeding control, and cost analysis after PK-guided transition to extended-half-life factor IX in hemophilia B: A multicentric studyMaria Chovi-Trull, Juan Eduardo Megías-Vericat, Tomás Palanques-Pastor, et al.
International Journal of Laboratory Hematology|October 6, 2018
Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiologyJosé María Bastida, Oriana López-Godino, Ana Vicente-Sánchez, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 12, 2021
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitorsMiguel Escobar, Giancarlo Castaman, Santiago Bonanad Boix, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Medicina Clinica|February 18, 2004
[Cloning and stem cells]Ximo Soriano Felipe, Antonio Guerrero Espejo, Santiago Bonanad Boix
Clinical Case Reports|January 14, 2022
Cerebral calcium embolismPedro Asensi Cantó, Jürgen Solís Ruíz, Pilar Lloret Madrid, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|April 5, 2022
Monitoring coagulation factors during surgery. A systematic reviewJuan Eduardo Megías-Vericat, Santiago Bonanad-Boix, María Remedios Marqués-Miñana, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|September 1, 2022
Emicizumab-induced photosensitivityPedro Asensi Cantó, Mercedes Rodríguez Serna, Pilar Lloret Madrid, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|November 6, 2024
Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in the therapy of hemophilia A in clinical practiceMaria Choví-Trull, Juan Eduardo Megías-Vericat, Santiago Bonanad Boix, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|February 14, 2025
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practiceMaria Choví-Trull, Juan Eduardo Megías-Vericat, Santiago Bonanad Boix, et al.
Hematology Reports|October 28, 2025
Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A PatientsMaria Choví-Trull, Juan Eduardo Megías-Vericat, Santiago Bonanad-Boix, et al.
Thrombosis Research|January 13, 2026
Improvements in pharmacokinetics, bleeding control, and cost analysis after PK-guided transition to extended-half-life factor IX in hemophilia B: A multicentric studyMaria Chovi-Trull, Juan Eduardo Megías-Vericat, Tomás Palanques-Pastor, et al.
International Journal of Laboratory Hematology|October 6, 2018
Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiologyJosé María Bastida, Oriana López-Godino, Ana Vicente-Sánchez, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 12, 2021
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitorsMiguel Escobar, Giancarlo Castaman, Santiago Bonanad Boix, et al.
Pageof 2